Rebekka Wild (IBS) won the Atip-Avenir program

on the October 6, 2020

Rebekka Wild from IBS and involved in Glyco@Alps is one of the Atip-Avenir prize winners 2020. The teams created as part of the Atip-Avenir program (Inserm / CNRS) aim to strengthen the host organization's research system by autonomously developing their own themes.
Rebekka Wild presents us her project:

"Our aim is to characterize the glycosaminoglycan (GAG) biosynthesis machinery on a molecular level. GAGs are complex polysaccharides, that are covalently attached to both cell surface and extracellular matrix proteins, thereby modulating the interaction with growth factors, cytokines, and many others. Malfunction of GAG biosynthesis has been linked to Alzheimer’s disease, chronic inflammation, tumorigenesis and diabetes. To gain a better understanding of the enzymes involved in GAG chain elongation and modification, we will combine high-resolution structural studies using cryo-electron microscopy with in vitro functional analysis."

Congratulations to Rebekka Wild for her success !

Published on October 14, 2020